Antares Pharma’s (NASDAQ:ATRS) Buy Rating Reaffirmed at HC Wainwright

Antares Pharma, Inc. (NASDAQ:ATRS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Wednesday, November 8th. They presently have a $3.50 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 92.31% from the stock’s previous close.

ATRS has been the topic of several other research reports. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 target price on the stock in a research note on Tuesday, July 18th. Piper Jaffray Companies set a $3.00 target price on shares of Antares Pharma and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $3.84.

Shares of Antares Pharma (ATRS) opened at $1.82 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69. Antares Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $4.09.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. sell-side analysts expect that Antares Pharma will post -0.11 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/antares-pharma-inc-atrs-given-buy-rating-at-hc-wainwright/1766293.html.

In other Antares Pharma news, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The disclosure for this sale can be found here. Corporate insiders own 11.60% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. California Public Employees Retirement System increased its stake in shares of Antares Pharma by 4.1% in the 3rd quarter. California Public Employees Retirement System now owns 972,694 shares of the specialty pharmaceutical company’s stock valued at $3,152,000 after acquiring an additional 38,394 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Antares Pharma by 2.0% in the 3rd quarter. Perceptive Advisors LLC now owns 4,353,897 shares of the specialty pharmaceutical company’s stock valued at $14,107,000 after acquiring an additional 86,644 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Antares Pharma by 5.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 560,936 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 27,360 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Antares Pharma by 28.3% in the 3rd quarter. Wells Fargo & Company MN now owns 1,335,906 shares of the specialty pharmaceutical company’s stock valued at $4,328,000 after acquiring an additional 294,810 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its stake in shares of Antares Pharma by 150.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after acquiring an additional 30,000 shares during the last quarter. 38.11% of the stock is owned by institutional investors.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.